Shintani Hideharu,
Department of Chemistry Chuo University, Japan
Ji li,
Department of Pharmacology and Toxicology State University of New York, USA
Journal of Pharmaceutical Regulatory Affairs represents one of the leading International online platforms for communication and exchange of scholarly information on the current and prevailing laws and the regulatory concepts as applicable to the development and commercialization of pharmaceutical & biomedical products; food; beverages; biotech products and cosmetics originating from across the world.
The journal publishes peer-reviewed articles under open access creative commons attribution license terms and are of immense relevance to the pharmacy students, physicians, clinicians, pharmaceutical & biopharmaceutical industrialists, regulatory affair professionals, manufacturers of medical devices and equipment, practicing attorneys, regulators, as well as academic and research community engaged in the designing and development of new drugs.
The journal offers wide coverage of topics including trends and guidelines of various National and International regulatory agencies, Pharmacovigilance, new drug application processes, protocols of achieving regulatory compliance, legislative revisions, regulatory approvals, marketing practices, as well as the formulation & streamlining of good manufacturing practice. The journal’s core focus is on the procedures, protocols, standards & policies, pharmaceutical regulations, quality control and quality assurance of drug development.
Rapid Publication Service
Hilaris Publishing is offering wide range of opportunities, options and services for the prospective authors to publish their scholarly contributions.
The journal caters to the demands of the fast publication without compromising on the editorial quality including manuscript peer-review. This flexibility is being provided to ensure earliest author credibility to their respective contributions and this will also ensure timely dissemination of research outcomes for efficient integration, effective translation and reduced redundancy.
Authors have the option to choose between the standard open access publication service which takes its own course of time for complete publication process or can opt for rapid publication service wherein the article is published at the earliest date (Includes multiple subject experts commissioning for securing earliest peer-review comments). The authors can avail this flexibility based on the personal preference, funding agency guidelines or Institutional or organizational requirements.
Regardless of the option, all manuscripts undergo thorough peer-review process, editorial assessment and production process.
Fast Editorial Execution and Review Process (FEE-Review Process)
Authors who are willing to publish their articles under this mode can make a pre-payment of $99 towards express peer-review and editorial decision. First editorial decision in 3 days and final decision with review comments in 5 days from the date of submission. Galley proof generation will be done in next 2 days from acceptance or maximum 5 days (For manuscripts notified for revision by external reviewer).
Manuscripts accepted for publication will be charged regular APC.
Authors retain the copyright of their publication and the final version of the article will be published in both HTML and PDF formats as well as XML formats for transmitting to indexing databases. The editorial team of the Journal will ensure adherence to scientific publication guidelines.
Articles published in Pharmaceutical Regulatory Affairs: Open Access have been cited by esteemed scholars and scientists all around the world. Pharmaceutical Regulatory Affairs: Open Access has got h-index 9 , which means every article in Pharmaceutical Regulatory Affairs: Open Access has got 9 average citations.
Pharmaceutical Regulatory Affairs: Open Access received 400 citations as per Google Scholar report
